Bordetella holmesii is a Gram-negative bacterium first identified in 1995. It can cause pertussis-like symptoms in humans. B. holmesii contains insertion sequences IS481 and IS1001, two frequently used targets in the PCR diagnosis of Bordetella pertussis and Bordetella parapertussis infections. 
INTRODUCTION
To date, eight different species are formally described in the genus Bordetella. Of them, Bordetella pertussis is the main causative agent of human pertussis (Kerr & Matthews, 2000) . Bordetella parapertussis can also cause pertussis-like symptoms in humans (Heininger et al., 1994; He et al., 1998) . Bordetella holmesii is a small Gram-negative coccobacillus first described in 1995, and it is oxidase negative, non-motile and produces soluble light-brown pigment when grown at 35 uC on heart infusion tyrosine agar (Weyant et al., 1995) . It has been cultivated from the blood, pleural fluid and sputum of immunocompromised patients (Lindquist et al., 1995; Tang et al., 1998; Morris & Myers, 1996 Muller et al., 1997; Lind-Brandberg et al., 1998; Loeffelholz et al., 1999; Heininger et al., 2000; Fry et al., 2004) . The genome of B. holmesii contains IS481-and IS1001-like elements (Reischl et al., 2001; Templeton et al., 2003) . The copy numbers of the IS481-and IS1001-like elements are estimated to be 8-10 (Reischl et al., 2001 ) and 3-5 (this study). This raises the concern that B. holmesii can cause false-positive results in PCR assays based on the detection of IS481 and IS1001.
We investigated the prevalence of B. holmesii in Finnish and Dutch patients with pertussis-like symptoms to find out whether B. holmesii could confound IS481-and IS1001-based assays. Clinical specimens were NP swabs collected from 2804 Finnish patients from 2000 to 2003, and from 8515 Dutch patients from 1992 to 2003. The Finnish methods used were a conventional IS481 PCR (He et al., 1993 (He et al., , 1996 and a B. holmesii-specific real-time PCR (LightCycler, Roche) described in this study. The target gene used in the PCR was recA, a gene encoding the RecA protein involved in homologous recombination in bacteria and regarded as a housekeeping gene (Favre & Viret, 1990; Favre et al., 1991; Kuhl, 1996; Pietilä et al., 2000) . The methods used in the Netherlands were IS481 and IS1001 PCR assays with conventional or real-time formats (van der Zee et al., 1993b (van der Zee et al., , 1996 Templeton et al., 2003) , and a newly developed B. holmesii-specific real-time PCR targeting the homologue of IS1001.
METHODS
Bacterial strains and culture. For development and validation of B. holmesii-specific real-time PCR, the 30 Bordetella strains used in Finland were 16 B. pertussis human isolates (Mooi et al., 1999; Gzyl et al., 2001; Wang et al., 2002) , four B. parapertussis strains (ATCC 15311 T and three human isolates) (He et al., 1998) , one Bordetella bronchiseptica strain (Central Public Health Laboratory, Colindale, UK), seven B. holmesii strains (ATCC 51541 T and six clinical isolates) (Yih et al., 1999) , one Bordetella avium strain (ATCC 35086 T ) and one Bordetella hinzii strain (ATCC 51730 T ). In addition, 47 clinical isolates from 16 bacterial species and four clinical isolates of Candida albicans were tested. The 16 bacterial species included Haemophilus influenzae (4), Haemophilus parainfluenzae (1), Staphylococcus aureus (4), Streptococcus pyogenes (4), Streptococcus pneumoniae (4), Streptococcus agalactiae (3), Neisseria meningitidis (1), Moraxella catarrhalis (3), Escherichia coli (4), Proteus mirabilis (4), Corynebacterium diphtheriae (2), Enterococcus faecalis (4), Enterococcus faecium (1), Pseudomonas aeruginosa (3), Klebsiella pneumoniae (3) and Klebsiella oxytoca (3). Bordetella strains were grown on charcoal agar, as described previously (He et al., 1993) . All other bacteria and the fungi were cultivated at the Department of Medical Microbiology, University of Turku, Turku, Finland, according to the methods described in the Manual of Clinical Microbiology published by the American Society for Microbiology. Bacterial colonies on the plates were harvested for isolation of DNA at the Pertussis Reference Laboratory, National Public Health Institute, Turku, Finland.
In Tilburg, the Netherlands, bacterial strains used for the development and validation of B. holmesii-specific real-time PCR were four B. pertussis strains, two B. parapertussis strains (human and sheep isolates), three B. bronchiseptica strains (human, dog and pig isolates), three B. holmesii strains (ATCC 51541 T and two clinical isolates), and one strain each of B. hinzii, Bordetella trematum and Bordetella petrii. Isolates were cultured on charcoal agar as described previously (van der Zee et al., 1993b) .
Isolation of DNA from bacterial cultures. In Finland, the High Pure PCR Template Preparation kit (Roche Applied Science) was used for isolation of DNA. Bacteria (~10 9 cells ml
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) harvested from the culture plates were placed in 300 ml PBS and DNA was extracted according to the manufacturer's instructions. DNA concentrations were measured by a spectrophotometer (SmartSpec 3000, Bio-Rad). DNA concentrations were adjusted to 5 ng ml 21 and the samples were stored at 220 uC.
In Tilburg, the Netherlands, for the isolation of DNA from bacteria, cells were suspended in 500 ml physiological saline supplemented with 1 mM EDTA (van der Zee et al., 1993b) Sequence analyses of the Bordetella recA gene and the IS1001 homologue in B. holmesii. Because IS481 associated with B. pertussis was also found in the B. holmesii genome, PCR that targets IS481 can detect B. holmesii. The Bordetella recA gene was chosen as the target for a specific PCR for the detection of B. holmesii, and its sequence was studied by PCR-based sequencing. Primers were designed based on the recA sequence of B. pertussis (Favre & Viret, 1990) . The primers RA1F and RA2R (Table 1) were used for B. pertussis, B. parapertussis and B. bronchiseptica. For B. avium, B. hinzii and B. holmesii, primers RA1F and RA3R (Table 1) were used. The purified PCR products were sequenced by the ABI PRISM BigDye Terminator v3.0 Cycle Sequencing kit (Applied Biosystems) with the same primers that were used in the PCR. The nucleotide sequences were analysed with BioEdit 5.0.9 Sequence Editor, and compared to sequences in GenBank using BLASTN search algorithms (Altschul et al., 1997; Jones et al., 2005) .
In the Netherlands, with primers BppA and BppZ based on IS1001 of B. parapertussis in the conventional PCR assay (van der Zee et al., 1996) (Table 1) , a DNA fragment was amplified from B. holmesii, using a lowered annealing temperature of 55 uC. Fragments obtained from three B. holmesii isolates were sequenced (Baseclear), analysed with BioEdit 5.0.9 Sequence Editor, and compared to sequences in GenBank using BLASTN search algorithms.
B. holmesii-specific real-time PCR. In Finland, for the real-time PCR, the primers were designed based on the recA sequence of B. holmesii (Table 1) , and the amplification reactions were carried out in a LightCycler (Roche Diagnostics). The 20 ml reaction mixture contained 2 ml LightCycler FastStart Reaction Mix SYBR Green I, 4 mM MgCl 2 , 4 % DMSO (Merck), 0?5 mM HrecAF and HrecAR primers, and 4 ml template DNA. The temperature profile included initial denaturation at 95 uC for 10 min, followed by 50 cycles of denaturation at 95 uC for 1 s, annealing at 64 uC for 3 s, and extension at 72 uC at 7 s. The temperature transition rate was 20 uC s 21 . Fluorescence was measured at the end of each extension phase. After amplification, a melting curve was constructed by heating the product at 20 uC s 21 to 95 uC, lowering the temperature at 20 uC s 21 to 40 uC for 170 s, and then heating at 0?1 uC s 21 to 97 uC. Fluorescence was measured through the slow-heating phase. Fluorescence data were converted to derivative melting curves by plotting the negative derivative of the fluorescence with respect to temperature against temperature [2(dF/dT) against T], and a specific melting temperature value (Tm) was obtained. In each run, B. holmesii DNA (5 pg ml 21 ) was used as positive control and the reagents, except template DNA, as negative control. The PCR product expected was 164 bp in length. A 16 ml sample of the PCR products was run on a 2 % Agarose MP gel (Roche) to confirm the correct size of the amplicon. To monitor inhibition of PCR, purified B. holmesii DNA was spiked into five DNA solutions randomly selected from the NP samples submitted for routine diagnosis of pertussis.
In Tilburg, the Netherlands, the B. holmesii PCR was performed separately in a volume of 25 ml containing 12?5 ml PCR mastermix (Eurogentec), 7?5 pmol Bh-F1 and Bh-R1 primers, and 4?4 pmol B. holmesii-specific probe (Bh1-NED). Both reaction mixtures were incubated at 50 uC for 2 min and preheated at 95 uC for 10 min, followed by 50 cycles of 15 s at 95 uC, and 1 min at 60 uC. PCR was performed on a 7900 HT Sequence Detection System (Applied Biosystems) with 9600 emulation.
Clinical specimens. In Finland, PCR has been routinely used since 1993 for the diagnosis of pertussis at the Department of Medical Microbiology, University of Turku (He et al. 1993 (He et al. , 1996 . NP swabs (dacron, Copan Diagnostics) were taken from patients with suspected pertussis at local health centres and hospitals, stored Isolation of DNA from NP swabs. In FInland, the dry NP swabs were first placed in 300 ml autoclaved and UV-irradiated in-house distilled water at room temperature for 15 min, briefly mixed by vortex, and 200 ml of the fluid was then heated at 94 uC for 10 min. DNA was extracted by the Roche kit and 10 ml was used for amplification. If not assayed immediately, the extracted DNA was stored frozen.
In Tilburg, dry swabs were suspended upon receipt in 500 ml physiological saline supplemented with 1 mM Tris/EDTA buffer. DNA was released by boiling the samples at 96 uC for 15 min. Inhibition was measured by addition of phocine herpes virus (PhHV) at a concentration 106 above the detection limit. Inhibited samples were further purified using the Qiagen DNA kit. Samples received after the year 2000 were purified using MagNaPure extraction (Total Nucleic Acid kit, Roche Molecular Biochemicals), with a final elution volume of 50 ml. Five microlitres were used for amplification.
In Amsterdam, dry swabs (dacron or cotton) were used. The tips of these swabs were cut and placed in tubes containing 300 ml PBS. Cells and other material originating from the patient were eluted from the swabs by shaking the tubes at room temperature for 30 min. After a short spin, 30 ml of the eluate was heated at 95 uC for 15 min. Further purification was done by traditional isopropanol precipitation. Two microlitres were used for the outer PCR reaction of the nested PCR.
PCR assays for detection of B. pertussis and B. parapertussis. In Finland, the PCR used for routine diagnosis of pertussis was a conventional PCR described previously (He et al., 1996) . In brief, the primers BP1 and BP2 chosen from IS481 of B. pertussis were used (Glare et al., 1990; He et al., 1993) (Table 1 ). The sensitivity of the PCR assay is~5 bacteria per reaction tube (He et al., 1996) . AmpliTaq Gold polymerase (Applied Biosystems) was used. The reaction mixture of 50 ml contained 50 mM KCl, 10 mM Tris/HCl (pH 8?3), 1?5 mM MgCl 2 , 0?01 % (v/v) gelatin, 200 mM deoxyribonucleotides, 20 pmol primers BP1 and BP2, 1 U polymerase, and 5 ml extracted DNA. Amplification was performed using a DNA Engine (MJ Research) with the following conditions: initial denaturation for 10 min at 95 uC, then 40 cycles of denaturation for 1 min at 95 uC, annealing for 1 min at 55 uC, extension for 1 min at 72 uC and a final extension step of 5 min at 72 uC. The PCR products were stored at 4 uC before gel electrophoresis was performed. The amplicons were separated by agarose gel electrophoresis and the bands were visualized after staining with ethidium bromide.
In Tilburg, PCR was performed as described previously with primers specific for IS481 and IS1001 (Table 1 ; van der Zee, 1993b). In the multiplex PCR assay, an internal control consisting of PhHV (Niesters, 2001; Templeton et al., 2003) was included (van der Zee, 1993b). In 2001, the conventional PCR was changed to a real-time format that required shorter amplicons than the former PCR. New primers were designed based on IS481 of B. pertussis and IS1001 of B. parapertussis (Table 1) . Different fluorescent probes ( To the outer PCR mixture, 2 ml nucleic acid solution was added to obtain a final volume of 25 ml. The PCR programme consisted of 1 step at 94 uC for 3 min followed by 30 cycles of 93 uC for 30 s, 58 uC for 30 s and 72 uC for 50 s, and a final extension step of 72 uC for 5 min, in the PTC200 DNA engine (MJ Research). After completion of the outer PCR, 2 ml was transferred to the inner PCR mixture, and the same PCR cycling programme was followed. The inner PCR products were separated on a 10 % acrylamide gel and stained with ethidium bromide. The length of the inner PCR fragments was indicative of the putative pathogen (Table 1) . Mixtures of culturepositive controls and a buffer sample as negative control were added in each test run.
RESULTS AND DISCUSSION
In Finland and the Netherlands, the nationwide vaccination programmes against pertussis were started in 1952 and 1953, respectively, and the vaccination coverage has been high (He et al., 1998; Mooi et al., 1998) . Despite the high coverage, pertussis has remained endemic and the incidence has increased in both countries. The two countries have also started to use IS481 PCRs for the diagnosis of pertussis, since 1992 and 1993 , respectively (van der Zee et al., 1996 He et al., 1996) . The diagnostic performance of the PCR assays is excellent and has proved to be stable. In the present study, the positivity rates obtained by IS481 PCR were similar in both countries.
B. holmesii has been isolated from the blood, pleural fluid and sputum of immunocompromised (Lindquist et al., 1995; Tang et al., 1998; Shepard et al., 2004) and immunocompetent patients (Ririe et al., 1997; Tang et al., 1998; Morris & Myers, 1998) . The role of B. holmesii as a cause of pertussis is not known, but this organism was isolated from NP specimens of patients with pertussis-like symptoms in the USA from 1994 to 1998 (Yih et al., 1999; Mazengia et al. 2000) . This has raised concerns about the role of B. holmesii as a cause of false diagnosis of B. pertussis and B. parapertussis infections, because B. holmesii also contains IS481. This sequence is almost identical to that in B. pertussis. B. holmesii also contains the IS1001-like element. The two IS elements are frequently used targets for the PCR diagnosis of B. pertussis and B. parapertussis infections, respectively. Some alternative detection methods for B. holmesii have also been published (Poddar, 2003; Vielemayer et al., 2004) .
Bordetella species-specific recA sequences and the IS1001 homologue in B. holmesii
Alternative targets for detection of Bordetella species were identified in this study. The recA sequences of Bordetella species were aligned using BLASTN search algorithms, and a segment corresponding to 1046 bp of B. holmesii recA was analysed. The sequence similarity of B. holmesii recA was highest (90 %) with B. hinzii recA (Fig. 1) . The corresponding similarities of B. holmesii recA to those of other Bordetella species were 87 % to B. pertussis, 87 % to B. parapertussis, 87 % to B. bronchiseptica and 86 % to B. avium (Fig. 1) . B. parapertussis and B. bronchiseptica recA had the highest sequence similarities to B. pertussis recA: 99?6 % and 99?8 %, respectively. The recA nucleotide sequences are available in the NCBI database and the accession numbers are AF399658 (B. pertussis), AF399659 (B. parapertussis), AF399657 (B. bronchiseptica), AY124330 (B. avium), AY124331 (B. hinzii) and AF399664 (B. holmesii).
The IS1001 fragments generated with primers BppA and BppZ (van der Zee et al., 1993a) from three isolates of B. holmesii were sequenced. The amplified fragments of the three isolates showed 97 % similarity, whereas similarity with IS1001 of B. parapertussis was about 87 %. By inverse PCR with primers directed outward of the obtained fragments, attempts were made to sequence the complete IS element. Analysis of flanking sequences revealed that the right inverted repeat was present and was almost identical to that of IS1001 in B. parapertussis. The left part of the IS element was lacking (data not shown). From the PCR reactions with outward primers, three to five DNA fragments were generated, suggesting that three to five copies of IS1001 are present in the genome of B. holmesii. The partial IS1001 nucleotide sequences of B. holmesii are available in the NCBI database and the accession numbers are AY786980-AY786982.
The recA sequences in the genus Bordetella appear to be species specific. Furthermore, no intra-species variation of the recA sequence was found when B. pertussis strains isolated in different countries and at different times were studied (Mooi et al., 1998; Gzyl et al., 2001; Wang et al., 2002) . The results agree with the earlier observation that B. pertussis is a homogeneous species and recently derived (van der Zee et al. Parkhill et al., 2003) . In addition, the partial IS1001 homologue in B. holmesii was sequenced and probably showed sufficient sequence variation to warrant a new IS designation. Unfortunately, no complete IS copy was isolated.
Specificity and sensitivity of real-time PCR assays
In this study, a B. holmesii-specific real-time PCR based on recA was developed, and the melting-curve analysis was used for specific detection of the amplicons (Ririe et al., 1997; Pietilä et al., 2000) . Also, a newly developed B. holmesiispecific real-time PCR targeting the homologue of IS1001 is described. The specificity of these PCRs proved to be high.
The specificity of the B. holmesii recA real-time PCR was tested by using serial 10-fold dilutions (0?005 pg ml (16 species) and fungal DNA. In addition, purified DNA preparations of B. petrii (50 ng ml
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) and B. trematum (60 ng ml 21 ) were examined. An amplification product was obtained from the DNA of B. holmesii, but not from those of other Bordetella species, except B. hinzii. Also, other non-Bordetella bacterial DNA and the fungal DNA gave a negative result. A small amount of amplification product was obtained from B. hinzii DNA, but the Tm of the product was 2 uC higher than that of B. holmesii. No primer dimers were detected when the 50-cycle amplification profile was used. Serial 10-fold dilutions of B. holmesii (ATCC 51541 T ) DNA (0?005 pg ml 21 -5 ng ml 21 ) were used to analyse sensitivity. The effect of DNA concentration on Tm was examined by analysing 10-fold dilutions of B. holmesii DNA (0?005 pg ml
-5 ng ml 21 ) in six parallel reactions in the same run (Fig. 2) . The mean Tm was 87?70 u C and the coefficient of variation was 0?16 %. The mean Tm value obtained by testing aliquots of the same sample (50 pg ml 21 ) in five separate runs was 87?69 uC, and the corresponding inter-assay coefficient of variation was 0?18 %. The mean Tm value obtained by testing aliquots of the same sample (50 pg ml 21 ) five times in the same run was 87?70 u C, and the corresponding intra-assay coefficient of variation was 0?03 %. The sensitivity of the PCR assay was 20 fg of DNA per reaction tube (~3 bacterial cells) (Fig. 2) . The analytical sensitivity of this assay was comparable to that of the conventional IS481 PCR.
The specificity of the IS1001-based real-time PCR for detection of B. holmesii was tested with all available Bordetella isolates, except Bordetella ansorpii (Ko et al., 2005) , which is a potential ninth species of Bordetella. Only B. holmesii was found to be positive. The sensitivity of the assay was 10 fg DNA per reaction tube (~2 bacterial cells).
In the Netherlands, both the real-time and conventional PCRs used the same targets, IS481 and IS1001, for the detection of B. pertussis and B. parapertussis. The real-time multiplex PCR for detection of B. pertussis and B. parapertussis was validated by comparison with the conventional assay. A random subset of 588 of 8515 clinical samples was investigated by both assays, and results were 100 % concordant. The sensitivity of the assay was 1 and 10 fg of B. pertussis and B. parapertussis DNA, respectively, per reaction tube (1-2 bacterial cells). In contrast to the conventional assay, primers based on IS1001 in the real-time assay did not detect B. holmesii.
The real-time PCR offers many advantages compared to conventional PCR, such as rapidity, and simultaneous amplification and detection. The post-amplification detection procedure is not usually needed, therefore the potential for contamination of amplicons is low (Exner & Lewinski, 2002; Teo et al., 2002) .
Detection of B. pertussis, B. parapertussis and B. holmesii in clinical specimens
This is the largest study of clinical material published to date to evaluate whether B. holmesii confounds PCR assays of IS481 and IS1001. 
Concluding remarks
To our knowledge, this is the first report to study the prevalence of B. holmesii infections in patients with pertussislike symptoms in European countries. We conclude that B. Table 2 . Number of NP samples tested by the PCR assays in the Netherlands holmesii is not among the causative agents of pertussislike symptoms in Finland and the Netherlands. It is of note that B. holmesii does not grow in culture if cephalexin is used (Mazengia et al., 2000) . The limited number of isolations from respiratory tract samples could be due to lack of awareness, because B. holmesii is not thought to be a common inhabitant of the respiratory tract. Although PCR is usually more sensitive than culture in the diagnosis of pertussis, both tests are usually positive in unvaccinated patients. The possibility of B. holmesii should be taken into account, especially when NP samples of unvaccinated patients are IS481 PCR positive but culture negative. These samples could be retested with PCR assays described in this study.
